



Press release 2014-06-24

Orders of Four C-RAD Systems from US Customers

C-RAD received two orders for in total four systems from customers in the US. Both orders include a Catalyst HD™ and a Sentinel 4DCT™ System.

Catalyst HD™ is based on the patented C-RAD technology. With a unique arrangement of multiple 3D cameras and newly developed software, the system is convincing with superior performance for all treatments where couch rotations are applied. The Catalyst HD™ has been developed to fulfill the clinical requirements of specifically high accuracy for motion control in stereotactic radiosurgery.

All existing C-RAD interfaces for respiratory gating and for treatment couch control for Varian and Elekta are compatible with the Catalyst HD™. Software modules for Patient Setup and Positioning, Motion Monitoring during treatment and Respiratory Gating are adapted to the system.

Stereotactic radiosurgery is a form of radiation therapy where the focused x-ray beam is delivered with very high accuracy into a small volume within the body. Therewith tumor tissue can be treated efficiently with minimizing the dose delivered to healthy tissue around the tumor. This treatment technique is especially used for head and neck treatments.

Tim Thurn, CEO, C-RAD AB:

“The Catalyst HD enjoys a high interest among our customers. Most of the new developed sales projects on the important US market include the Catalyst HD system. C-RAD will present the system at the AAPM conference in Austin, TX in the second half of July. The overall order intake during the second quarter is developing well.”

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 28 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company's first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier. Erik Penser Bankaktiebolag is appointed as C-RAD's Certified Adviser. For more information on C-RAD, please visit www.c-rad.com.



For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666947, E-mail investors@c-rad.com

The above information is price sensitive and must therefore be disclosed under the Securities Market Act (2077:528).